Fixed drug eruption induced by topical olopatadine ophthalmic solution.

Abstract

Fixed drug eruption (FDE) usually develops after oral administration and is described as a cutaneous reaction recurring at the same location each time the drug is taken. Olopatadine is both a H1 histamine receptor antagonist and a mast cell stabilizer, indicated for the treatment of allergic conjunctivitis. Here, we report a 14-year-old male patient who developed FDE localised on the lateral side of periorbital rim bilaterally, whilst applying olopatadine 0.1% ophthalmic solution for the treatment of allergic conjunctivitis. As far as we know, FDE due to olopatadine has not been previously reported in the literature. We deem it appropriate to report this case because FDE that results from the application of topical drugs is a rare event in the literature.

• Authors: S G Bilgili, A S Karadag, R Karadag, G Bulut, O Calka
• Journal: Human & experimental toxicology (Hum Exp Toxicol) Vol. 31 Issue 12 Pg. 1292-4 (Dec 2012) ISSN: 1477-0903 [Electronic] England
• PMID: 22531967 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Dibenzoxepins
• Ophthalmic Solutions
• Olopatadine Hydrochloride

Topics

• Administration, Topical
• Adolescent
• Anti-Inflammatory Agents, Non-Steroidal (adverse effects)
• Conjunctivitis, Allergic (complications, drug therapy)
• Dibenzoxepins (adverse effects)
• Drug Eruptions (etiology, pathology)
• Humans
• Male
• Olopatadine Hydrochloride
• Ophthalmic Solutions (adverse effects)
• Orbit (drug effects, pathology)
• Orbital Diseases (chemically induced, pathology)